ELOX
NASDAQEloxx Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$13.66+3.41 (+33.27%)
2026-06-092026-06-23
News · 26 weeks29+125%
2025-12-282026-06-21
Mix2990d
- Insider16(55%)
- SEC Filings7(24%)
- Other5(17%)
- Offering1(3%)
Latest news
25 items- INSIDERLarge owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERNew insider Domicilium Real Estate Fund Iii Lp claimed ownership of 14,285 shares (SEC Form 3)3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERSEC Form 4 filed by Director Kjellson Nina S4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERSEC Form 4 filed by Director Webster Stephen W4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERSEC Form 4 filed by Director Walts Alan Edmund4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERSEC Form 4 filed by Director Rubin Steven D4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Aggarwal Sumit4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- SECSEC Form 424B4 filed by Eloxx Pharmaceuticals Inc.424B4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form EFFECT filed by Eloxx Pharmaceuticals Inc.EFFECT - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- PREloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to NasdaqARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of $10.99 per pre-funded warrant, which equals the pub
- SECSEC Form CERT filed by Eloxx Pharmaceuticals Inc.CERT - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- INSIDERLarge owner Domicilium Real Estate Fund Iii Lp disposed of 113,636 shares (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- SECAmendment: SEC Form S-1/A filed by Eloxx Pharmaceuticals Inc.S-1/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form 8-A12B filed by Eloxx Pharmaceuticals Inc.8-A12B - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECAmendment: SEC Form S-1/A filed by Eloxx Pharmaceuticals Inc.S-1/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECEloxx Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- INSIDERSEC Form 3 filed by new insider Webster Stephen W3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kjellson Nina S3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERLarge owner Coastlands Capital Lp disposed of 1,250,000 shares (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERDirector Rubin Steven D converted options into 1,875 shares, increasing direct ownership by 15% to 14,625 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERPresident and CEO Aggarwal Sumit exercised 472,826 shares at a strike of $0.08 and was granted 1,000,000 shares, increasing direct ownership by 737% to 1,672,756 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERDirector Walts Alan Edmund converted options into 1,875 shares, increasing direct ownership by 14% to 15,567 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- SECSEC Form DEF 14C filed by Eloxx Pharmaceuticals Inc.DEF 14C - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form S-1 filed by Eloxx Pharmaceuticals Inc.S-1 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form 10-Q filed by Eloxx Pharmaceuticals Inc.10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
ELOX FAQ
6 questionsWhat does Eloxx Pharmaceuticals Inc. do?
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.Where does ELOX stock trade?
Eloxx Pharmaceuticals Inc. (ELOX) is listed on NASDAQ.What sector and industry is ELOX in?
Eloxx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about ELOX?
Eloxx Pharmaceuticals Inc. has had 4 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $400.00 price target on 2021-12-17. Recent price targets range from $100.00 to $400.00.What companies are similar to ELOX?
Notable peers in the same industry include SUPN (Supernus Pharmaceuticals Inc.), ANIP (ANI Pharmaceuticals Inc.), ZYME (Zymeworks Inc.). Compare ELOX side-by-side with any of them on Quantisnow.How can I track ELOX on Quantisnow?
Quantisnow aggregates Eloxx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELOX to receive live email and push alerts on every new disclosure.